645 Preclinical development of a novel colon-targeted therapeutic for the treatment of immune checkpoint inhibitor (ICI)-colitis

• Sumanta Pal,
• Nazli Dizman,
• JoAnn Hsu,
• Nicholas Salgia,
• Milton L Greenberg,
• Andrew C Newman,
• Jonathan Skupsky,
• Zeynep Zengin,
• Luis Meza,
• Neal Chawla,
• Sabrina Salgia,
• Jasnoor Malhotra

Affiliations

Sumanta Pal

Aff1 grid.410425.60000000404218357City of Hope, Duarte Duarte CA USA

Nazli Dizman

Aff1 0000 0004 0421 8357grid.410425.6Department of Medical Oncology & Experimental TherapeuticsCity of Hope Comprehensive Cancer Center 1500 East Duarte Road 91010 Duarte CA USA

JoAnn Hsu

Aff5 0000 0004 0421 8357grid.410425.6Department of Medical Oncology & Therapeutics ResearchCity of Hope Comprehensive Cancer Center Duarte CA USA

Nicholas Salgia

Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center Duarte, Duarte, California, USA

Milton L Greenberg

3Vivreon Gastrosciences, Inc., San Diego, CA, USA

Andrew C Newman

3Vivreon Gastrosciences, Inc., San Diego, CA, USA

Jonathan Skupsky

4VA Long Beach, Long Beach, CA, USA

Zeynep Zengin

2City of Hope Comprehensive Cancer Center, Duarte, CA, USA

Luis Meza

2City of Hope Comprehensive Cancer Center, Duarte, CA, USA

Neal Chawla

2City of Hope Comprehensive Cancer Center, Duarte, CA, USA

Sabrina Salgia

2City of Hope Comprehensive Cancer Center, Duarte, CA, USA

Jasnoor Malhotra

2City of Hope Comprehensive Cancer Center, Duarte, CA, USA